Share
Other content recommended for you
- Update on disease-modifying therapies for multiple sclerosis
- Disease modifying therapies for relapsing multiple sclerosis
- Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline
- Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial
- Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data
- Disease-modifying therapies for multiple sclerosis
- Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
- Systematic literature review and network meta-analysis in highly active relapsing–remitting multiple sclerosis and rapidly evolving severe multiple sclerosis
- ▼Dimethyl fumarate for relapsing-remitting multiple sclerosis
- ▼Teriflunomide for multiple sclerosis